In a large cohort with a 23-month median follow-up of the CIRCULATE-Japan GALAXY observational study, ctDNA-based detection of molecular residual disease was predictive of survival outcomes and benefit of adjuvant chemotherapy in patients with resectable colorectal cancer.
- Yoshiaki Nakamura
- Jun Watanabe
- Eiji Oki
